Lucid Diagnostics Inc.
LUCD
Positions held
Your positionsLUCD isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $124.14M | Enterprise value | $114.57M | Trailing P/E | — | Forward P/E | -3.94 |
| PEG | — | Price / book | 11.41 | Beta | 1.12 | Dividend yield | 0.00% |
| Revenue growth | 26.7% | Earnings growth | — | Gross margin | -21.7% | Operating margin | -8.7% |
| Profit margin | 0.0% | ROE | -5.6% | ROA | -81.6% | Debt / equity | 2.28 |
| Current ratio | 1.33 | Free cash flow | -$26.43M | Analyst recommendation | strong_buy | Mean target | $4.00 |
| 52w high | $1.63 | 52w low | $0.50 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $1.5M | $1.3M | $1.5M | $1.2M | $1.2M | — |
| Op margin | -868.5% | -964.5% | -931.6% | -971.0% | -978.8% | — |
| Net income | -$11.7M | -$13.9M | -$16.3M | -$10.4M | -$4.4M | — |
| Gross margin | 2.0% | -29.4% | -23.7% | -40.1% | -34.4% | — |
| Gross profit | $0.0M | -$0.4M | -$0.4M | -$0.5M | -$0.4M | — |
| Operating income | -$12.8M | -$12.1M | -$14.0M | -$11.8M | -$11.4M | — |
- Revenue +17% vs prior quarter ($1.5M vs $1.3M).
- Gross margin 2% (was -29.4% prior quarter).
- Operating margin expanded to -868.5%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $4.7M | $4.3M | $2.4M | $0.4M |
| Op margin | -1054.8% | -1059.6% | -1996.8% | -14920.7% |
| Net income | -$58.0M | -$45.5M | -$52.7M | -$56.2M |
| Gross margin | -41.7% | -63.3% | -146.3% | -858.6% |
| Gross profit | -$2.0M | -$2.8M | -$3.6M | -$3.2M |
| Operating income | -$49.6M | -$46.1M | -$48.5M | -$56.3M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-22 · Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways
2026-08-20 · Lucid Diagnostics (LUCD) Q2 2026 Earnings Call Transcript
2026-08-15 · Lucid Diagnostics Eyes Medicare Catalyst for EsoGuard Growth
2026-08-14 · PAVmed Inc. Q2 2026 Earnings Call Summary
2026-08-14 · PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results
2026-08-14 · Lucid Diagnostics Inc. Q2 2026 Earnings Call Summary
2026-08-13 · Lucid Diagnostics Inc (LUCD) (Q2 2026) Earnings Call Highlights: Strategic Pivot to High-Value ...
2026-08-13 · Lucid Diagnostics Q2 Earnings Call Highlights
2026-08-13 · Lucid Diagnostics Inc. (LUCD) Reports Q2 Loss, Lags Revenue Estimates
2026-08-13 · Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results
2026-08-12 · Earnings To Watch: Lucid Diagnostics Inc (LUCD) Q2 2026 -- GF Value Sees 5% Upside
2026-08-06 · Pulse Biosciences, Inc (PLSE) Reports Q2 Loss, Misses Revenue Estimates
Price (daily)
Full chart · RSI · MACD · patterns